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Abstract
Objective—Mindfulness-based cognitive therapy (MBCT) is a programme developed to prevent 
depression relapse, but has been applied for other disorders. Our objective was to systematically 
review and meta-analyse the evidence on the effectiveness and safety of MBCT for the treatment 
of mental disorders.
Methods—Searches were completed in CENTRAL, MEDLINE, EMBASE, LILACS, 
PsychINFO, and PsycEXTRA in March 2011 using a search strategy with the terms ‘mindfulness-
based cognitive therapy’, ‘mindfulness’, and ‘randomised controlled trials’ without time 
restrictions. Selection criteria of having a randomised controlled trial design, including patients 
diagnosed with mental disorders, using MBCT according to the authors who developed MBCT 
and providing outcomes that included changes in mental health were used to assess 608 reports. 
Two reviewers applied the pre-determined selection criteria and extracted the data into structured 
tables. Meta-analyses and sensitivity analyses were completed.
Results—Eleven studies were included. Most of them evaluated depression and compared 
additive MBCT against usual treatment. After 1 year of follow-up MBCT reduced the rate of 
relapse in patients with three or more previous episodes of depression by 40% (5 studies, relative 
risk [95% confidence interval]: 0.61 [0.48, 0.79]). Other meta-analysed outcomes were depression 
and anxiety, both with significant results but unstable in sensitivity analyses. Methodological 
quality of the reports was moderate.
Conclusion—Based on this review and meta-analyses, MBCT is an effective intervention for 
patients with three or more previous episodes of major depression.
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Introduction
Mental disorders account for 13% of the global burden of disease, represent a significant 
burden of disability, and are projected to continue to rise (World Health Organization, 2004). 
Mindfulness-based cognitive therapy (MBCT) (Segal et al., 2002), initially developed to 
prevent relapse or recurrence of major depressive disorder (MDD), is now being studied to 
treat a variety of mental health disorders. The purpose of this research was to conduct a 
systematic review and meta-analysis of randomised controlled trials (RCTs) assessing the 
efficacy and safety of MBCT for the treatment of mental disorders.
MBCT is a programme in which contemplative practices and cognitive therapy techniques 
are combined and delivered by MBCT-trained therapists in standard 8-week units (Segal et 
al., 2002). The patient visits the therapist, participates in cognitive therapy sessions, and 
learns mindfulness techniques, breathing and physical exercises of relaxation. Patients are 
coached to continue these exercises at home through recordings and notes.
The number of practitioners who use the technique is growing – nurses, nurse practitioners, 
physicians, psychologists, counselors, etc. MBCT has been described in the nursing 
literature as an innovative approach to relieve distress for individuals suffering from medical 
and psychiatric illnesses (O’Haver Day and Horton-Deutsch, 2004). Priority 
recommendations for the implementation of the National Institute for Health and Clinical 
Excellence new depression guidelines include managing depression in people with physical 
and chronic illnesses and include using group-based cognitive-behaviour therapy (Kendrick 
and Peveler, 2010). Nurses and advanced practice nurses interested in mental healthcare are 
often eager to trial novel or alternative therapeutic approaches. Evidence of efficacy, 
indications and specific patient populations is necessary to support implementation of 
therapeutic interventions.
The number of studies assessing the efficacy of MBCT is growing as well; therefore, a 
systematic description is needed. Systematic reviews on MBCT have been published (Chiesa 
and Serretti, 2011; Coelho et al., 2007; Fjorback et al., 2011; Hofmann et al., 2010; Piet and 
Hougaard, 2011). However, this review differs by including solely RCTs, by conducting 
sensitivity analyses on drop-out rates, and by having a different analytic strategy.
Methods
A systematic protocol was developed and implemented for this research (Galante, 2009).
Literature search and study selection
In March 2011 the following databases were searched: CENTRAL, MEDLINE, EMBASE, 
LILACS, PsychINFO, and PsycEXTRA. The terms ‘mindfulness-based cognitive therapy’, 
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‘meditation’ and ‘mindfulness’, and ‘randomised controlled trials’ were used with language 
limit of English and Spanish. Two reviewers independently excluded reports that did not 
meet inclusion criteria based on title and abstract. Full published reports were obtained for 
the remainder, and inclusion criteria were applied. References were scanned for further 
RCTs.
Included studies had to: (1) be RCTs; (2) include patients with mental disorders diagnosed 
according to the Diagnostic and Statistical Manual of Mental Disorders (American 
Psychiatric Association, 2012), the International Statistical Classification of Diseases (World 
Health Organization, 2012) or a validated diagnostic scale; (3) deliver MBCT according to 
recommendations of Segal and colleagues (2002), or with minimal adaptations made but still 
called MBCT by the study authors; and (4) include a change in mental health as an outcome 
variable.
Data abstraction
The data were extracted independently by two reviewers and entered into data extraction 
forms designed for the review. Studies were assessed for methodological quality according 
to the Cochrane Reviewers’ Handbook assessment tool (The Cochrane Collaboration, 2008). 
Disagreements between reviewers were satisfactorily resolved by discussion.
Analysis
Studies were grouped according to the type of outcome investigated and the follow-up 
period. In studies in which authors divided their patient populations into groups, the 
divisions for analysis were retained. Data obtained using the same measure and which were 
reported as continuous variables (or scales with a sufficient number of points to treat 
variables as continuous) were pooled using the weighted mean difference (WMD) with a 
95% confidence interval (95% CI). When different measures were used to evaluate the same 
result in a comparison, data were grouped by calculating the standardised mean difference 
(SMD) with 95% CI. Final values were used. Dichotomous outcomes were analysed by 
calculating relative risk (RR) grouped in each comparison.
In order to determine whether combining the results was appropriate, χ2 and I2 tests of 
heterogeneity were performed. The p-value for χ2 was set conservatively at 0.1. I2 band 
values were interpreted according to the Cochrane Reviewers’ Handbook (The Cochrane 
Collaboration, 2008), which recommends interpreting I2 values below 40% as non-
significant heterogeneity. Subgroup analyses were done according to type of disorder, stage, 
co-morbidities and multifactorial interventions. The potential effect of publication bias was 
assessed by analysing funnel plot asymmetries when meta-analysis of at least five studies 
could be carried out and when no significant heterogeneity was found. To obtain more 
conservative estimates a random effects model for the meta-analyses was used. Finally, 
sensitivity analyses were conducted to explore the influence of studies with significant 
dropout rates (>20%) on effect size. Results are reported according to QUOROM guidelines 
(Moher et al., 1999).
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Eleven studies meeting selection criteria were identified (Figure 1). The characteristics of 
included studies are provided in Table 1. Some of the studies were reported in multiple 
publications. Data could not be obtained for three conference papers either because efforts to 
contact the authors were unsuccessful, or because authors did not supply the requested 
information after contacting them (Fearson and Chadwick, 2007; Katzman et al., 2003; 
Welch, 2005). All but one study compared MBCT to treatment as usual (TAU) (Segal et al., 
2010). As a conservative approach the study reported by Kuyken et al. (2008) was included 
in the MBCT + TAU versus TAU because 25% of the MBCT patients continued their 
medication.
Table 2 outlines the methodological quality of included reports. Due to the nature of the 
intervention, double blinding cannot be implemented with interventionists. However, most 
studies blinded evaluators and interviewers to intervention. Allocation concealment was 
adequate in all of the studies. Some reports did not include all outcomes listed in methods. 
Therefore, there is the potential for publication bias. In the majority of the reports 
randomisation method was not fully described.
Effects of the intervention
Meta-analyses were conducted for results including relapse rates, depression (scales were 
not mixed because same studies reported different scales) and anxiety (mixed scales). Stress 
and quality of life were reported in more than one study, but the scales for each were too 
distinct to standardise and combine for a meta-analysis. Other outcomes were reported with 
insufficient data to conduct meta-analyses. Adverse effects were not assessed in any of the 
studies.
Relapse rate at 1 year post-intervention for patients with three or more 
previous episodes of depression—As shown in Figure 2, 430 participants contributed 
to this outcome. Of participants in the MBCT + TAU group 38% relapsed, compared to 62% 
in the TAU group. The difference between the two groups was significant in favour of 
MBCT + TAU (RR [95% CI]: 0.61 [0.48, 0.79]). No statistical heterogeneity was identified 
(p = 0.22, I2 = 31%). The number needed to treat to avoid a relapse was 4 (95% CI 2.6–9.1).
Subgroup analysis examined patients with MDD (≥3 episodes) in remission receiving 
MBCT alone or in combination with support (MBCT+) to discontinue or reduce the amount 
of anti-depressant medications (ADs) taken. The overall result in the MBCT alone subgroup 
was significant (RR [95% CI]: 0.55 [0.43–0.70]) with absence of heterogeneity (p = 0.45) 
(I2 = 0%). Results remained unchanged with sensitivity analysis (RR [95% CI]: 0.66 [0.52, 
0.85]) (Figure 3).
Depression measured with HAM-D at 1 year post-intervention
The Hamilton Rating Scale for Depression (HAM-D) scale ranges from 0 (minimal 
depression) to 53 (severe depression) (Hamilton, 1967). There is no consensus on the 
clinically significant difference. However, a difference of 3–3.1 points has been considered 
valid (National Collaborating Centre for Mental Health, 2004).
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As shown in Figure 4, 242 participants contributed to this outcome. The difference in 
depression mean scores between the MBCT + TAU group and the TAU group was 
significant in favour of MBCT + TAU (WMD [95% CI]: −2.46 [−4.36 to −0.56]). This result 
suggests that MBCT + TAU decreased the average degree of depression at 1-year post-
intervention compared to TAU. The result of the overall χ2 test for heterogeneity was not 
significant (p = 0.99, I2 = 0%), indicating that combining these studies was appropriate.
In sensitivity analysis results did not remain stable (Figure 5). While results continue to 
favour the MBCT + TAU group, they were no longer significant (WMD [95% CI]: −2.42 
[−5.40, 0.55]). There was no statistical heterogeneity (p = 0.87, I2 = 0%).
Depression measured with BDI-II at 1 year post-intervention
The Beck Depression Inventory – second edition (BDI-II) ranges from 0 (minimal 
depression) to 63 (severe depression) (Beck et al., 1996), and a difference of 5 points is 
considered clinically relevant (Hiroe et al., 2005).
As shown in Figure 6, 190 participants contributed to this outcome. The difference in 
depression mean scores between the MBCT + TAU group and the TAU group was 
significant in favour of MBCT + TAU (WMD [95% CI]: −10.39 [−15.66 to 5.12]). There 
was no statistical heterogeneity (p = 0.50, I2 = 0%) and findings were clinically significant. 
Sensitivity analysis could not be conducted due to only two studies contributing to this 
outcome.
Depression measured with HAM-D at post-intervention
As shown in Figure 7, 316 participants contributed to this outcome. The difference in 
depression mean scores between the MBCT + TAU group and the TAU group was 
significant in favour of MBCT + TAU (WMD [95% CI]: −4.31 [−5.79 to −2.83]). The result 
of the χ2 test for heterogeneity was not significant (p = 0.79, I2 = 0%). This result suggests 
that MBCT + TAU decreased the average degree of depression at post-intervention 
compared to TAU using HAM-D. Results remained stable in sensitivity analysis (WMD 
[95% CI]: −3.88 [−6.07, −1.69]) (Figure 8).
Depression measured with BDI-II at post-intervention
As shown in Figure 9, 291 participants contributed to this outcome. The meta-analysis of the 
BDI-II scale favoured MBCT + TAU intervention: the average degree of depression 
decreased (WMD [95% CI]: −7.33 [−12.12, −2.54]) compared to TAU. This difference is 
clinically significant; however, there was statistical heterogeneity (p = 0.002, I2 = 73%), 
which cautions the appropriateness of combining the studies.
Subgroup analysis examined the effect of MBCT alone or in combination with support to 
discontinue or reduce the amount of ADs taken by patients with MDD (≥3 episodes) in 
remission or with current depression and a history of suicidal ideation. The heterogeneity of 
the overall effect of the meta-analysis may have been influenced by data from the first 
group. The likely cause of these results can be tracked by comparing the studies. Although 
patient profiles and interventions were similar between arms in the study conducted by 
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Godfrin and van Heeringen (2010) there was a significant loss of patient follow-up (22.2% 
in one group and 34.6% in the other), likely contributing to the gap between subgroups. The 
remainder of the subgroups analysed included only one study in each.
Sensitivity analysis (Figure 10) excluded the study by Godfrin and van Heeringen and 
statistical heterogeneity disappeared (p = 0.20, I2 = 35%). Results remained stable (WMD 
[95% CI]: −5.68 [−9.88, −1.49]).
Anxiety at post-intervention
As Figure 11 shows, 149 participants contributed to this outcome, which favoured MBCT + 
TAU intervention: the average degree of anxiety decreased compared to TAU (SMD [95% 
CI]: −0.42 [−0.74, −0.09]). The result of the tests for heterogeneity were not significant (p = 
0.55, I2 = 0%). Anxiety was measured with different scales in each of the studies (Foley et 
al., 2010; Williams et al., 2008). Because patients are heterogeneous, differences may be due 
to subgroup differences rather than to the use of different scales.
Evaluation of publication bias
Funnel plots (Figures 12 and 13) do not show major asymmetry, indicating that there is no 
clear evidence of publication bias. However, due to the low number of studies this bias could 
not be assessed for all outcomes.
Discussion
The main results indicate that MBCT + TAU are more effective at preventing episodes or 
prolonging time between episodes of depression than TAU alone. Patients with recurrent 
depression (≥3 episodes) treated with MBCT + TAU have on average 40% fewer relapses 
compared to patients undergoing TAU alone. One relapse is avoided for every four patients 
treated with MBCT in comparison to those receiving TAU. This effect is statistically 
significant and remained stable under sensitivity analysis. Given that MBCT teaches 
techniques that should be practiced on a daily basis to maintain its effectiveness over time, 
long-term studies are particularly important. Rate of relapse was the primary outcome of the 
majority of the studies identified and included in this systematic review and meta-analysis; 
therefore sample sizes were calculated for relapse rates giving methodological robustness to 
our findings. Furthermore, a relapse rate is a more robust and objective measure compared to 
self-reported measures. Depressive symptoms at 1 year post-intervention measured by 
HAM-D and BDI-II scales were statistically significant (and clinically significant at least in 
the case of HAM-D), but did not remain stable. New trials with adequate methodological 
quality are needed to further evaluate this outcome.
Unsurprisingly, the results of the meta-analysis of individuals who had two previous 
episodes of depression at one year of follow-up (data not demonstrated) showed no 
significant differences. The particular difference in the number of previous episodes of 
depression is supported by the hypothesis of differential activation (Teasdale, 1988). This 
hypothesis states that with each new relapse in depression the strength of the association 
between negative mood and dysfunctional patterns of thought and rumination increases in 
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such a way that every time it is less necessary for a stressful stimulus to reproduce the 
relapse.
In a recent study that could not be meta-analysed because of the unique comparison groups, 
recurrently (>1 episode) depressed patients in remission were randomised to receive ADs, 
MBCT plus a discontinuation of ADs, or placebo instead of ADs (Segal et al., 2010). After 
18 months of follow-up results showed that among unstable remitters, patients in both 
MBCT and ADs showed a 73% decrease in hazard of relapse compared with placebo (p = 
0.03). In contrast, stable remitters showed no differences. These results suggest that MBCT 
offers protection against relapse on par with that of maintenance AD pharmacotherapy. This 
was the most important result with intent-to-treat or available case analysis among the 
reported studies that could not be meta-analysed.
Other significant single RCT results with intent-to-treat or available case analysis at one year 
of follow-up comparing MBCT to TAU include a reduction in the number of diagnosed 
psychiatric co-morbidities (Kuyken et al., 2008), a reduction of depressive symptoms and 
anger, an increase of strength and an improvement in the quality of life (Foley et al., 2010; 
Godfrin and van Heeringen, 2010). MBCT was also shown to do as well as group cognitive 
therapy in decreasing social phobia symptoms (Piet et al., 2010). However, there were no 
significant differences for the use of ADs (Teasdale et al., 2000), the amount, duration, 
severity and degree of distress of relapses, quality of life measured by the OMS scale, the 
total cost of treatment per year during the year of follow-up (Kuyken et al., 2008), and 
fatigue and tension (Godfrin and van Heeringen, 2010). The remainder of the results 
included in this systematic review had shorter or no follow-up periods so it is uncertain 
whether the results are maintained over time.
MBCT has been predominantly implemented for depressive patients. However, as seen in 
medical, nursing, and other arenas involved in mental healthcare, depression is a symptom 
that is present in many psychiatric and psychological conditions; therefore, the theoretical 
foundations of MBCT are relevant to the whole spectrum of mental health pathologies. 
Moreover, depression is highly prevalent in patients with physical illness and in aging 
populations. The populations analysed in most studies included in this review suffered from 
serious and recurrent depression. More RCTs to evaluate the intervention in populations 
with less severity are needed.
Comparing results with other reviews
Two systematic reviews on MBCT RCT’s without meta-analyses were published before 
(Coelho et al., 2007; Fjorback et al., 2011). Findings in the current study agree with Coelho 
et al. (2007) and Fjorback et al. (2011) in highlighting that because of the nature of the 
control groups results cannot be attributed to specific effects of MBCT. More clinical studies 
with long-term follow-up are needed to better understand and confirm specific effects of 
MBCT. Problems which can surface when traditional statistical analyses are applied to 
interventions in which groups are used were also pointed out previously (Williams et al., 
2008). Groups of patients are able to influence each other’s outcomes and thus variables are 
no longer necessarily independent.
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A systematic review and meta-analysis on MBCT was recently published (Chiesa and 
Serretti, 2011) in which non-randomised trials were included and more conservative 
analyses were conducted by presenting diagnostic subgroup analyses only. Nonetheless, in 
spite of the differences between Chiesa’s work and the current review, the main conclusions 
are similar.
Piet and Hougaard (2011) published another systematic review on MBCT that included 
patients with MDD only. Their findings on relapse prevention were similar to those of this 
review, but they added a meta-analysis including MDD patients with any number of episodes 
and the results were significant (RR = 0.66 for MBCT compared to treatment as usual or 
placebo controls). Other differences with this review are that Piet and Hougaard were less 
conservative when including Kuyken et al.’s study in a meta-analysis comparing MBCT 
against ADs (yet getting not significant results), that they did not have a previous formal 
protocol, that they did not use the Cochrane tool to assess the methodological quality of the 
studies, and that they did not explore drop-out rates in sensitivity analyses. Piet and 
Hougaard (2011) made a final remark we found interesting: that it may be premature to 
exclude patients with 2 MDD relapses from future studies since not enough data have been 
collected.
A meta-analytic review was published (Hofmann et al., 2010) on the effect of mindfulness-
based therapies on depression and anxiety, obtaining moderate effect sizes. However, as this 
analysis is pre-post and uncontrolled, the validity of the results is much lower than that of 
meta-analyses of RCTs, such as those presented in this review.
Limitations
Important limitations of the current review are the low number of studies in the meta-
analyses and the fact that only dichotomous variables were used to measure relapse rates. In 
addition, mental health problems are chronic or long-term conditions but outcomes were not 
reported to assess long-term effects beyond the first year of follow-up.
Although participants in all the reported studies were depressed or had been depressed in the 
past, the heterogeneity among studies was high. To counter this limitation subgroup analyses 
were conducted. Although this study was performed as per the version of the Cochrane 
Handbook available at the time, a new version is now in place (The Cochrane Collaboration, 
2011). The most relevant update concerning this review is that the risk of bias table was 
slightly expanded. Finally, the search strategy used to support this review was thorough. 
However, grey literature data could have been further assessed through contacting key 
informants.
Despite these limitations it is concluded that MBCT is an effective tool at least for patients 
with three or more previous episodes of major depression.
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With increasing use of MBCT across a range of practitioners, the clinical relevance of 
MBCT can be considered. Findings from this systematic meta-analysis can be used to 
inform nurses and other mental health practitioners on the efficacy, patient population 
and type of mental illnesses which best respond to MBCT technique based on findings 
from randomised control trials.
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Key points for policy, practice and research
• Patients with recurrent depression (three episodes or more) treated with 
additive MBCT have on average 40% fewer relapses at one year of 
follow-up compared to patients undergoing treatment as usual.
• Improvements in depression and anxiety with additive MBCT were 
significant at one year of follow-up but unstable in sensitivity analyses.
• More studies with active control groups and long-term follow-ups are 
needed to better understand the specific effects of MBCT.
• Depression is a symptom that is present in many conditions. More high 
quality RCTs are needed to evaluate MBCT in populations with 
varying depression severity as well as diagnosis with multiple co-
morbidities.
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Study selection flow chart.
*Citations that were present in more than one database.
**For some studies more than one report was published.
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Meta-analysis (risk ratio). Relapse rate at 1 year post-intervention for patients with 3 or 
more previous episodes of depression.
MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; 95% CI: 95% 
confidence interval; M-H: Mantel–Haenszel; random: random effects model; epis: episodes.
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Sensitivity analysis (risk ratio). Relapse rate at 1 year post-intervention for patients with 3 or 
more previous episodes of depression.
MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; 95% CI: 95% 
confidence interval; M-H: Mantel–Haenszel; random: random effects model; epis: episodes.
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Meta-analysis (mean difference). Depression measured with HAM-D at 1 year post-
intervention. MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: 
standard deviation; 95% CI: 95% confidence interval; IV: inverse variance; epis: episodes; 
disc: discontinue; HAM-D: Hamilton rating scale for depression; ADM: antidepressant 
medication.
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Sensitivity analysis (mean difference). Depression measured with HAM-D at 1 year post-
intervention.
MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: standard 
deviation; 95% CI: 95% confidence interval; IV: inverse variance; epis: episodes; disc: 
discontinue; HAM-D: Hamilton rating scale for depression; ADM: antidepressant 
medication.
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Meta-analysis (mean difference). Depression measured with BDI-II at 1 year post-
intervention. MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: 
standard deviation; 95% CI: 95% confidence interval; IV: inverse variance; epis: episodes; 
disc: discontinue; BDI: Beck depression inventory; ADM: antidepressant medication.
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Meta-analysis (mean difference). Depression measured with HAM-D at post-intervention. 
MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: standard 
deviation; 95% CI: 95% confidence interval; IV: inverse variance; epis: episodes; disc: 
discontinue; HAM-D: Hamilton rating scale for depression; ADM: antidepressant 
medication.
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Sensitivity analysis (mean difference). Depression measured with HAM-D at post-
intervention. MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: 
standard deviation; 95% CI: 95% confidence interval; IV: inverse variance; epis: episodes; 
disc: discontinue; HAM-D: Hamilton rating scale for depression; ADM: antidepressant 
medication.
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Meta-analysis (mean difference). Depression measured with BDI-II at post-intervention. 
MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: standard 
deviation; 95% CI: 95% confidence interval; IV: inverse variance; epis: episodes; disc: 
discontinue; BDI: Beck depression inventory; ADM: antidepressant medication.
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Sensitivity analysis (mean difference). Depression measured with BDI-II at post-
intervention. MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: 
standard deviation; 95% CI: 95% confidence interval; IV: Inverse variance; epis: episodes; 
disc: discontinue; BDI: Beck depression inventory; ADM: antidepressant medication.
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Meta-analysis (standardised mean difference). Anxiety at post-intervention.
MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: standard 
deviation; 95% CI: 95% confidence interval; IV: inverse variance; epis: episodes.
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Funnel plot to evaluate publication bias. Relapse rate at 1 year post-intervention for patients 
with 3 or more previous episodes of depression.
MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: standard 
deviation; 95% CI: 95% confidence interval; IV: inverse variance; epis: episodes; disc: 
discontinue; ADM: antidepressant medication; SE: standard error; RR: relative risk.
Galante et al. Page 25














Funnel plot to evaluate publication bias. Depression measured with BDI-II at post-
intervention. MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; SD: 
standard deviation; 95% CI: 95% confidence interval; IV: inverse variance; epis: episodes; 
disc: discontinue; ADM: antidepressant medication; SE: standard error; MD: mean 
difference; curr depr: current depression.
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